Xenetic to advance DNase programme with UVA partnership

2024-01-18

引进/卖出免疫疗法临床研究

Xenetic to advance DNase programme with UVA partnership

Preview

来源: Pharmaceutical Technology

Under the agreement, the parties will develop Xenetic’s DNase-based platform. Credit: Maksim Shmeljov/Shutterstock.com.

Xenetic Biosciences has entered into research funding and material transfer agreements with the University of Virginia (UVA) in the US to advance its systemic deoxyribonuclease (DNase) programme.

The parties will develop Xenetic’s DNase-based oncology platform.

The platform acts on neutrophil extracellular traps (NETs), weblike structures that comprise extracellular chromatin covered with histones and other proteins.

The new initiative addresses NETs associated with inflammatory and autoimmune diseases, as well as cancer progression.

Excessive levels of NETs can create pro-tumorigenic niches that may limit the effectiveness of cancer therapies.

The platform is designed to complement existing cancer treatments including immunotherapies.

The agreements grant Xenetic an option to solely license any new intellectual property resulting from the DNase research programme. This is in addition to advancing the existing intellectual property of Xenetic.

Xenetic scientific advisory board member and UVA School of Medicine Department of Surgery chair Allan Tsung will oversee the research.

The company is preparing for a first-in-human clinical trial to assess DNase plus immune checkpoint inhibitors or chemotherapy.

Xenetic CEO Jeffrey Eisenberg stated: “We believe the data generated by our research and development collaborations are key to fully unlocking the potential of our DNase technology and importantly, providing translational insights as we drive a clinical path for our lead solid tumour indications.

“These agreements provide a significant addition to our development capabilities and resources, and we believe it bolsters our opportunity to accelerate development timelines.

“Additionally, we are pleased to deepen our work with Dr Tsung, who has provided a valuable perspective to our team and significant insight for our DNase platform.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构